Abstract
Kynurenic acid (KYNA), one of the metabolites belonging to the kynurenine pathway, has been described as an important neuroprotective compound, its unbalancing being associated with several pathological conditions. In human brain, the majority of KYNA production is sustained by kynurenine aminotransferase II (KAT II). A selective KAT II inhibitor would be an important pharmacological tool, since it would reduce KYNA formation without causing complete depletion of this neuroprotector. (S)-(4)-(ethylsulfonyl)benzoylalanine (S-ESBA), described as a potent and selective inhibitor of rat KAT II, is unfortunately ineffective towards the human enzyme although the two orthologs share a remarkably high degree of sequence identity. We investigated the molecular basis for this intriguing species-specificity by adopting a site-directed mutagenesis and structural approach. We propose that the source of the inhibitor specificity toward the rat enzyme could reside on S-ESBA interaction/interference with a flexible loop that controls ligand admission to the active site by a classical induced-fit mechanism. Our data further highlights that even in case of highly conserved molecular targets, the flexibility of catalytically important structural elements can have a significant impact on the selectivity of inhibitor action.
Keywords: Kynurenic acid, kynurenine aminotransferase II, PLP-enzymes, crystal structure, conformational flexibility, drug design, cognition enhancing drugs, drug selectivity, S-ESBA, ligand, L-tryptophan, mammals, kynurenines, neuroactive, NMDA receptor, 7 nicotinic receptor, schizophrenia, Neurochemistry studies, dopamine, PLP-KYN, ketoacid, PMP, KAT II, mAAT, L-KYN, QUIN, hKAT II, Asp230, Tyr233, Tyr74, Arg399, isozymes, enzymes, PCR-based, homogeneity, X-ray, DNA sequencing, oligomeric, Bradford assay, albumine, Protein aliquots, UV/HPLC, ESRF, MOSFLM, SCALA, 3OH-KYN, ketoglutarate, IC50 value, catalysis, kinetics, mutant, wild-type, co-crystallization, stabilization, N-terminal
Current Topics in Medicinal Chemistry
Title: Biochemical and Structural Investigations on Kynurenine Aminotransferase II: An Example of Conformation-Driven Species-Specific Inhibition?
Volume: 11 Issue: 2
Author(s): Valentina Casazza, Franca Rossi and Menico Rizzi
Affiliation:
Keywords: Kynurenic acid, kynurenine aminotransferase II, PLP-enzymes, crystal structure, conformational flexibility, drug design, cognition enhancing drugs, drug selectivity, S-ESBA, ligand, L-tryptophan, mammals, kynurenines, neuroactive, NMDA receptor, 7 nicotinic receptor, schizophrenia, Neurochemistry studies, dopamine, PLP-KYN, ketoacid, PMP, KAT II, mAAT, L-KYN, QUIN, hKAT II, Asp230, Tyr233, Tyr74, Arg399, isozymes, enzymes, PCR-based, homogeneity, X-ray, DNA sequencing, oligomeric, Bradford assay, albumine, Protein aliquots, UV/HPLC, ESRF, MOSFLM, SCALA, 3OH-KYN, ketoglutarate, IC50 value, catalysis, kinetics, mutant, wild-type, co-crystallization, stabilization, N-terminal
Abstract: Kynurenic acid (KYNA), one of the metabolites belonging to the kynurenine pathway, has been described as an important neuroprotective compound, its unbalancing being associated with several pathological conditions. In human brain, the majority of KYNA production is sustained by kynurenine aminotransferase II (KAT II). A selective KAT II inhibitor would be an important pharmacological tool, since it would reduce KYNA formation without causing complete depletion of this neuroprotector. (S)-(4)-(ethylsulfonyl)benzoylalanine (S-ESBA), described as a potent and selective inhibitor of rat KAT II, is unfortunately ineffective towards the human enzyme although the two orthologs share a remarkably high degree of sequence identity. We investigated the molecular basis for this intriguing species-specificity by adopting a site-directed mutagenesis and structural approach. We propose that the source of the inhibitor specificity toward the rat enzyme could reside on S-ESBA interaction/interference with a flexible loop that controls ligand admission to the active site by a classical induced-fit mechanism. Our data further highlights that even in case of highly conserved molecular targets, the flexibility of catalytically important structural elements can have a significant impact on the selectivity of inhibitor action.
Export Options
About this article
Cite this article as:
Casazza Valentina, Rossi Franca and Rizzi Menico, Biochemical and Structural Investigations on Kynurenine Aminotransferase II: An Example of Conformation-Driven Species-Specific Inhibition?, Current Topics in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/156802611794863599
DOI https://dx.doi.org/10.2174/156802611794863599 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Discovery of Novel Compounds Targeting DJ-1 as Neuroprotectants for Parkinson’s Disease by Virtual Screening and In Silico Method
Current Computer-Aided Drug Design Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Aporphines and Parkinson’s Disease: Medical Tools for the Future
Current Topics in Medicinal Chemistry Drug-Induced Impulse Control Disorders: A Review
Current Clinical Pharmacology AKT: A Potential Target for Thyroid Cancer Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Current Progress in Molecular Responses to Acidosis in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Threat Posed by Persistent Organochlorine Pesticides and their Mobility in the Environment
Current Organic Chemistry L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Functional and Structural Alterations of Large Arteries: Methodological Issues
Current Pharmaceutical Design Experimental Developments and Review of Recent Patents for the Repair of Skeletal Muscles by Methods of Regenerative Medicine
Recent Patents on Regenerative Medicine Cutaneomeningospinal Angiomatosis (Cobb Syndrome) in a Young Patient
CNS & Neurological Disorders - Drug Targets Antidepressant Like Effects of Alternanthera sessilis and Clerodendrum infortunatum Leaves Extract in Immobility Models
The Natural Products Journal Pharmacological Management of Acutely Agitated Schizophrenic Patients
Current Pharmaceutical Design Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl]Carbamic acid with Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Chromatin Structure and Epigenetics of Tumour Cells: A Review
Cardiovascular & Hematological Disorders-Drug Targets Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics The Role of Physical Activity in the Development and Prevention of Overweight and Obesity in Childhood
Current Nutrition & Food Science Role of Genetic Factors in the Pathogenesis of Radial Deficiencies in Humans
Current Genomics